We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$342M
AUM Growth
+$4.53M
Cap. Flow
+$2.54M
Cap. Flow %
0.74%
Top 10 Hldgs %
27.24%
Holding
105
New
9
Increased
44
Reduced
37
Closed
6

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$8.51M
2
UHS icon
Universal Health Services
UHS
+$7.3M
3
ABBV icon
AbbVie
ABBV
+$6.16M
4
RAD
Rite Aid Corporation
RAD
+$5.54M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.74M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$10.6M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$8.41M
3
CELG
Celgene Corp
CELG
+$6.93M
4
BIIB icon
Biogen
BIIB
+$6.92M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$5.75M

Sector Composition

Rank Sector Weight
1 Healthcare 78.72%
2 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
CALL
Johnson & Johnson
JNJ
$618B
$14.9M 4.37%
+140,000
New +$14.5M
ALKS icon
2
Alkermes
ALKS
$8.22B
$11.4M 3.34%
266,000
+98,000
+58% +$4.39M
UHS icon
3
Universal Health Services
UHS
$10.2B
$10.3M 3.02%
98,700
+68,700
+229% +$7.3M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$9.62M 2.82%
58,000
-35,000
-38% -$5.75M
BIIB icon
5
Biogen
BIIB
$30B
$9.59M 2.81%
29,000
-21,000
-42% -$6.92M
SLXP
6
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$8.44M 2.47%
54,000
+10,507
+24% +$1.52M
GILD icon
7
Gilead Sciences
GILD
$162B
$7.66M 2.24%
72,000
-108,000
-60% -$10.6M
CELG
8
DELISTED
Celgene Corp
CELG
$7.58M 2.22%
80,000
-76,781
-49% -$6.93M
MDT icon
9
Medtronic
MDT
$109B
$6.87M 2.01%
+133,800
New +$8.51M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.6B
$6.64M 1.94%
92,000
-58,000
-39% -$3.81M
COV
11
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$6.58M 1.93%
76,000
-95,000
-56% -$8.41M
ABBV icon
12
AbbVie
ABBV
$443B
$6.41M 1.88%
+111,000
New +$6.16M
NKTR icon
13
Nektar Therapeutics
NKTR
$2.39B
$6.13M 1.8%
33,867
+16,534
+95% +$3.16M
TMO icon
14
Thermo Fisher Scientific
TMO
$213B
$5.96M 1.75%
49,000
+16,000
+48% +$1.95M
NPSP
15
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$5.82M 1.71%
224,000
+157,000
+234% +$4.51M
CVS icon
16
CVS Health
CVS
$133B
$5.73M 1.68%
72,000
+22,000
+44% +$1.73M
ACAD icon
17
Acadia Pharmaceuticals
ACAD
$4.43B
$5.42M 1.59%
219,000
-11,000
-5% -$257K
RAD
18
DELISTED
Rite Aid Corporation
RAD
$5.41M 1.58%
55,900
+42,900
+330% +$5.54M
INCY icon
19
Incyte
INCY
$24.2B
$5.25M 1.54%
107,000
-26,000
-20% -$1.3M
BMY icon
20
Bristol-Myers Squibb
BMY
$133B
$5.07M 1.48%
99,000
+14,000
+16% +$699K
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$121B
$4.83M 1.41%
43,000
-58,600
-58% -$5.58M
AGN
22
DELISTED
Allergan plc
AGN
$4.83M 1.41%
20,000
-5,000
-20% -$1.12M
REGN icon
23
Regeneron Pharmaceuticals
REGN
$78.5B
$4.6M 1.35%
13,000
-9,500
-42% -$3.18M
PCYC
24
DELISTED
PHARMACYCLICS INC
PCYC
$4.46M 1.31%
38,000
-17,000
-31% -$1.94M
CAH icon
25
Cardinal Health
CAH
$53.9B
$4.42M 1.29%
59,000
-40,000
-40% -$2.91M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Rhenman & Partners Asset Management held 105 positions worth $342M, up 1.3% from $337M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q3 2014 filing shows 9 new, 44 increased, 37 reduced and 6 closed positions. Its largest new stake was Medtronic: 133,800 shares worth $6.87M. The largest sale was Gilead Sciences, an estimated $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 85% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q3 2014 buy was Medtronic: 133,800 shares worth $6.87M.
  • Rhenman & Partners Asset Management added most to Universal Health Services in Q3 2014, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Myriad Genetics in Q3 2014, selling an estimated $3.11M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $342M portfolio in Q3 2014.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 6 in Q3 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.3% quarter-over-quarter to $342M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2014, filed 3 Nov 2014.